

TABLE OF CONTENTS

THEORY, PRACTICE, AND INSTRUCTIONS FOR USE	10
Background.....	10
Rationale Underlying the Pedagogy	11
Organization.....	12
How to Use the Lecture Modules	13
CONSULTATION.....	15
ACKNOWLEDGEMENTS	16
RELATED ARTICLES	16
CONTRIBUTORS	17

VOLUME I: A CURRICULUM & TEACHING MATERIALS

PART I: INTRODUCTION TO THE ASCP'S MODEL CURRICULUM

PREFACE.....	25
Using the Model Curriculum to Teach Medical Students, Primary Care Physicians and Other Health Professionals.....	27
RATIONALE.....	28
ORGANIZATION OF A PSYCHOPHARMACOLOGY PROGRAM.....	28
Relationship of Research to Training	29

PART II: THE CORE CURRICULUM

OVERVIEW AND EDUCATIONAL OBJECTIVES	30
Knowledge.....	30
Skills	31
WHAT AND HOW TO TEACH.....	35
The Didactic Program	35
Organization of Courses and Lectures	35
Special Considerations Related to Lectures.....	36
• Issues, Concepts and a Template.....	38
• Specific Lecture Topics.....	42
• Lectures on Psychosocial Topics.....	49

Literature Review Seminar	51
Case Conference	54
Computers and Psychopharmacology.....	55
• General	56
• Research	56
• Journals.....	57
• Organizations.....	57
• Personal Digital Assistants (PDAs).....	57
Supervision	58
• Introduction	58
• Background.....	59
• Rationale.....	59
• Clinical Mentorship Teaching Using Selected Case Material	63
• Supervision in Drug Clinics, Inpatient Units and Emergency Rooms	64
Off-Label Prescribing	65
Reading Materials	65
• Textbooks	65
• Journals and Newsletters	66
Neuroscience Lecture Series.....	69
Psychopharmacology Units	70
HOW TO EVALUATE	72
Formal Examination.....	72
Charting Patterns.....	73
Evaluation by Supervisor.....	75
Trainee Evaluation of Supervision and of the Program.....	76
Accreditation Issues	76
Relevant Websites.....	76
FINAL PEARLS.....	77
Professionalism.....	77
Words of Wisdom.....	77

PART III: CURRICULA FOR SPECIAL AREAS

CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY	79
Child and Adolescent Lecture Series	80
Child and Adolescent Instruments and Rating Scales	81
GERIATRIC PSYCHOPHARMACOLOGY	82
Geriatric Lecture Series	82
ALCOHOL AND SUBSTANCE ABUSE PSYCHOPHARMACOLOGY	83
Alcohol and Substance Abuse Lecture Series	83

PART IV: APPENDICES

APPENDIX A: Objective Assessment Measures: Rating Scales	84
APPENDIX B: List of Other Useful Books	93
APPENDIX C: List of Additional Journals	96
APPENDIX D: Books and Associations for Families of the Mentally Ill.....	98
APPENDIX E: Forms for Evaluation of Trainee, Clinical Supervisor, Teaching Faculty, and of Entire Course.....	100
APPENDIX F: An Investigative Psychiatry Curriculum for Residents	114
APPENDIX G: Guidelines for Pharmacotherapy Follow Up Visits and Quality of Care.....	118
APPENDIX H: Psychopharmacology Algorithms	121
APPENDIX I: Psychopharmacology and the Internet.....	122
APPENDIX J: GeneMedRx Drug Interaction Software by Clinicians, For Clinicians.....	124
APPENDIX K: Reading List for ASCP Certification Exam.....	125
APPENDIX L: First Draft of a Recommended Reading List for Residents.....	127

VOLUME II: LECTURE MODULES

OVERVIEW

INSTRUCTIONS FOR USE OF LECTURE MODULES	7
INSTRUCTIONS FOR USE OF AADPRT CD ON PEDAGOGY, EXAMPLES: “SCHIZOPHRENIA” and “DEPRESSION”	8
ASCP COMMITTEE ON RESIDENCY AND FELLOWSHIP DEPRESSION MODULE 2010 INSTRUCTION MANUAL	10
Project Overview	10
Components of the Depression Module.....	12
Suggestions for the Use of the Depression Module.....	12
ORGANIZATION OF LECTURES.....	16
Questions.....	17
LECTURING USING ANOTHER TEACHER’S SLIDES	17
USE OF CD ROMS	17
CONSULTATION – HELP IN USING THIS CURRICULUM.....	17

COURSES

Crash Course – David N. Osser (Editor)

<u>Antipsychotics</u>	101.1 – 101.23
▪ David N. Osser, M.D.	
<u>Medicine for Bipolar Disorder</u>	102.1 – 102.25
▪ Theo Manschreck, M.D., MPH, James W. Jefferson, M.D.	
<u>Antidepressants</u>	103.1 – 103.16
▪ David N. Osser, M.D.	
<u>Anti-Anxiety Agents</u>	104.1 – 104.13
▪ David N. Osser, M.D.	
<u>Drug-Drug Interactions 101</u>	105.1 – 105.18
▪ Jessica R. Oesterheld, M.D.	
<u>Therapeutic Alliance and Adherence</u>	106.1 – 106.18
▪ James M. Ellison, M.D., MPH	
<u>Art of Psychopharmacology</u>	107.1 – 107.4
▪ Ira D. Glick, M.D., Richard Balon, M.D.	

Basic Course

<u>Psychopharmacology in the Emergency Room</u>	201.1 – 201.20
▪ Michael D. Jibson, M.D.	
<u>Pharmacokinetics of Psychotropic Drugs</u>	202.1 – 202.31
▪ Terence A. Ketter, M.D.	
<u>Schizophrenia and Antipsychotic Medications (Two Hours)</u>	203.1 – 203.32
▪ Michael D. Jibson, M.D., Ira D. Glick, M.D.	
<u>Bipolar Disorders (Four Parts, Two Hours)</u>	204A.1 – 204D.28
▪ James W. Jefferson, M.D.	
<u>Bipolar Depression</u>	205.1 – 205.22
▪ Terence A. Ketter, M.D.	
<u>Antidepressant Pharmacotherapy</u>	206.1 – 206.21
▪ Charles DeBattista, M.D.	
<u>Treatment Resistant Depression</u>	207.1 – 207.16
▪ Charles DeBattista, M.D.	
<u>Electroconvulsive Therapy</u>	208.1 – 208.19
▪ Samuel O. Sostre, M.D., Charles H. Kellner, M.D., Max Fink, M.D.	
<u>Substance Abuse</u>	209.1 – 209.33
▪ Herbert Kleber, M.D., Eric Peselow, M.D., Steven Ross, M.D.	
<u>Sleep Disorders</u>	210.1 – 210.32
▪ Daniel F. Kripke, M.D.	
<u>Psychopharmacology of Violence</u>	211.1 – 211.24
▪ Leslie Citrome, M.D., MPH	
<u>Traumatic Brain Injury</u>	212.1 – 212.25
▪ Jonathan M. Silver, M.D., Stuart C. Yudofsky, M.D., Robert Hales, M.D.	

Advanced Course

<u>Combining Pharmacotherapy and Psychotherapy</u>	301.A – 301.18
▪ Ira D. Glick, M.D.	
<u>Mood Disorders in Women of Child Bearing Age</u>	302.1 – 302.23
▪ Katherine E. Williams, M.D., Natalie Rasgon, M.D., Ph.D.,	
<u>Atypical Depression</u>	303.1 – 303.15
▪ Jonathan W. Stewart, M.D., Donald Klein, M.D.	
<u>Panic Disorder</u>	304.1 – 304.32
▪ R. Bruce Lydiard, Ph.D., M.D.	
<u>Generalized Anxiety Disorder</u>	305.1 – 305.22
▪ R. Bruce Lydiard, Ph.D., M.D.	

<u>Social Anxiety Disorder/Social Phobia</u>	306.1 – 306.24
▪ R. Bruce Lydiard, Ph.D., M.D., James Ellison, M.D., MPH	
<u>Post-Traumatic Stress Disorder</u>	307.1 – 307.20
▪ Thomas A. Mellman, M.D., R. Bruce Lydiard, Ph.D., M.D., Howard A. Fenn, M.D.	
<u>Obsessive Compulsive Disorder</u>	308.1 – 308.23
▪ Wayne K. Goodman, M.D.	
<u>Personality Disorders</u>	309.1 – 309.29
▪ Larry J. Siever, M.D.	
<u>Eating Disorders</u>	310.1 – 310.14
▪ B. Timothy Walsh, M.D.	
<u>Body Dysmorphic Disorder</u>	311.1 – 311.12
▪ Katharine A. Phillips, M.D.	
<u>Psychopharmacology and the HIV-Positive Patient</u>	312.1 – 312.15
▪ Lawrence M. McGlynn, M.D., Peter H. Marcus, M.A.	
<u>Psychopharmacology of Sexual Dysfunction</u>	313.1 – 313.15
▪ R. Taylor Segraves, M.D., Ph.D.	
<u>Sexual Dysfunction Associated With Psychiatric Disorders and Psychiatric Drugs</u>	314.1 – 314.19
▪ R. Taylor Segraves, M.D., Ph.D.	

VOLUME III: LECTURE MODULES (CONT.)

Lectures Which Can Be Included In Any Course or May Be Optional

<u>Neurobiology of Psychiatric Illness</u>	401.1 – 401.41
▪ Hugh Brent Solvason, Ph.D., M.D.	
<u>Evidence Based Medicine in Mental Health</u>	402.1 – 402.27
▪ James M. Ellison, M.D., MPH, Leslie Citrome, M.D., MPH	
<u>Herbal Psychopharmacology</u>	403.1 – 403.33
▪ James W. Jefferson, M.D.	
<u>Brain Stimulation Therapies for Treatment Resistant Depression</u>	404.1 – 404.16
▪ John P. O'Reardon, M.D.	
<u>Cross-Cultural Psychopharmacology</u>	405.1 – 405.29
▪ Edmond H. Pi, M.D., Weiguo Zhu, M.D., Ph.D.	
<u>Psychopharmacology in the Primary Care Setting</u>	406.1 – 406.32
▪ Sarah K. Rivelli, M.D., Robert McCarron, M.D., Roger G. Kathol, M.D.	
<u>Epidemiology and Treatment of Depression in Patients With Chronic Medical Illness</u>	407.1 – 407.17
▪ Wayne J. Katon, M.D., R. Bruce Lydiard, Ph.D., M.D.	

<u>Evaluating the Research Literature</u>	408.1 – 408.22
▪ Eric Peselow, M.D.	
<u>An Ethical Framework for Clinician/Industry Interactions</u>	409.1 – 409.18
▪ Michael D. Jibson, M.D.	
<u>Clinical Trials</u>	410.1 – 410.12
▪ John M. Kane, M.D.	
<u>Mental Retardation</u>	411.1 – 411.20
▪ David Janowsky, M.D.	
<u>When and How to Use Clozapine</u>	412.1 – 412.18
▪ David N. Osser, M.D., Sachin Phansalkar, M.D.	
<u>Basic Neuroscience</u>	413.1 – 413.16
▪ Stephen M. Stahl, M.D.	

Child and Adolescent Psychopharmacology

<u>Maintaining the Alliance in Modern Pediatric Pharmacotherapy Practice</u>	501.1 – 501.16
▪ Shashank V. Joshi, M.D, FAAP	
<u>Using and Teaching Evidence-Based Medicine in Child Psychiatry</u>	502.1 – 502.9
▪ Vishal Madaan, M.D., Christopher J. Kratochvil, M.D.	
<u>Pediatric Psychopharmacology: General Principles</u>	503.1 – 503.14
▪ Shashank Joshi, M.D., Kiki Chang, M.D.	
<u>Antipsychotic Adverse Effects in Children and Adolescents</u>	504.1 – 504.16
▪ Christoph U. Correll, M.D.	
<u>Psychopharmacology of Autism</u>	505.1 – 505.17
▪ Christopher J. McDougle, M.D.	
<u>Childhood Onset Schizophrenia: Evaluation and Treatment</u>	506.1 – 506.17
▪ Antonio Y. Hardan, M.D., Vishal Madaan, M.D.	
<u>ADHD: Assessment and Treatment Across the Lifespan</u>	507.1 – 507.29
▪ Shashank V. Joshi, M.D., FAAP, Jessica R. Oesterheld, M.D.	
<u>Emerging Issues in the Treatment of Impulsive Aggression in Children and Adolescents</u>	508.1 – 508.19
▪ Peter S. Jensen, M.D.	
<u>An Overview of Pediatric Depression</u>	509.1 – 509.15
▪ Cynthia R. Pfeffer, M.D.	
<u>The Use of Medications for Pediatric Bipolar Disorder</u>	510.1 – 510.
▪ Kiki D. Chang, M.D.	

<u>Assessment and Treatment of Childhood Anxiety Disorders</u>	511.1 – 511.14
▪ John Walkup, M.D.	
<u>Childhood OCD</u>	512.1 – 512.13
▪ Vishal Madaan, M.D.	
<u>PTSD in Youth</u>	513.1 – 513.14
▪ Vishal Madaan, M.D., Christopher J. Kratochvil, M.D.	
<u>Tourette’s Disorder</u>	514.1 – 514.10
▪ Vishal Madaan, M.D.	

Geropsychiatry Psychopharmacology

<u>Dementia</u>	601.1 – 601.24
▪ Gary W. Small, James H. Ellison, M.D., MPH	
<u>Delirium</u>	602.1 – 602.32
▪ Barbara Kamholz, M.D.	
<u>Psychosis in Dementia</u>	603.1 – 603.14
▪ Dilip V. Jeste, M.D.	
<u>Pharmacological Treatment of Aggression in Dementia</u>	604.1 – 604.14
▪ Howard H. Fenn, M.D.	
<u>Depression in the Elderly</u>	605.1 – 605.22
▪ Gary W. Small, M.D., James M. Ellison, M.D., MPH	
<u>Bipolar Disorders in Late Life</u>	606.1 – 606.15
▪ Robert C. Young, M.D., Benoit H. Mulsant, M.D.	
<u>Anxiety Disorders in the Elderly</u>	607.1 – 607.20
▪ Eric Lenze, M.D.	
<u>Schizophrenia and Aging</u>	608.1 – 608.16
▪ Dilip V. Jeste, M.D.	
<u>Alcohol and Sedative-Hypnotic Addiction in the Elderly</u>	609.1 – 609.15
▪ David W. Oslin, M.D.	
<u>Drug-Drug Interactions in the Elderly</u>	610.1 – 610.11
▪ Bruce G. Pollock, M.D., Ph.D.	

Alcohol and Substance Abuse Psychopharmacology

<u>Brain and Behavior: Substance Abuse</u>	701.1 – 701.2
▪ Charles P. O’Brien, M.D., Ph.D., Charles Dackis, M.D.	
<u>Addiction: A Disease of the Brain</u>	702.1 – 702.12
▪ Charles P. O’Brien, M.D., Ph.D.	
<u>Substance Abuse: The Nation’s Number One Health Problem</u>	703.1 – 703.8
▪ James Cornish, M.D.	

<u>Marijuana</u>	704.1 – 704.13
▪ Daniel D. Langleben, M.D.	
<u>Stimulants</u>	705.1 – 705.17
▪ Charles Dackis, M.D.	
<u>Nicotine: A Drug of Abuse</u>	706.1 – 706.21
▪ Janet Audrain-McGovern, Ph.D.	
<u>Alcoholism</u>	707.1 – 707.12
▪ David W. Oslin, M.D.	
<u>Hallucinogenic Agents</u>	708.1 – 708.15
▪ Laura F. McNicholas, M.D., Ph.D.	
<u>Prescription Drug Abuse</u>	709.1 – 709.11
▪ Kyle M. Kampman, M.D.	
<u>Psychiatric Disorders and Psychotherapy of Substance Abuse</u>	710.1 – 710.13
▪ Robert M. Weinrieb, M.D.	
<u>Effects of Drugs on the Developing Brain: Pregnancy, Adolescence and Beyond</u>	711.1 – 711.10
▪ Marina Goldman, M.D.	
<u>Medical Complications of Substance Abuse</u>	712.1 – 712.27
▪ Phil Green, M.D.	